NCT07215468View on ClinicalTrials.gov

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
HIV -1 Infection
Interventions
DRUG

TMB-365

A monoclonal antibody acts as a HIV post-attachment inhibitor to be given intravenously

DRUG

TMB-380

A broadly neutralizing antibody (bNAb) against HIV to be given intravenously

DRUG

Baseline ART

Baseline ART to be taken daily and orally

All Listed Sponsors
lead

TaiMed Biologics Inc.

INDUSTRY